RxDoctor Payments Data

Miguel Bryce, MD

Clinical Cardiac Electrophysiology · Tavares, FLNPI 1558398784

Payments from drug & device makers

$13,569in general payments, 2019–2025

Across 195 payments — averaging $69.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Abbott$2K
  • Boston Scientific$775
  • Cvrx, Inc.$528
  • Impulse Dynamics (USA) Inc.$311
  • Kestra Medical Technology Services, Inc.$274
  • plus $1K from 11 others

What the payments were for

  • Travel & lodging$4,96637%
  • Food & beverage$8,53563%
  • Education$680%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,569 in reported general payments places this provider in the 20th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$583,870
Medicare patients
2,104
Services billed
8,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban486$535,122
XareltoRivaroxaban90$118,651
EntrestoSacubitril/Valsartan32$47,171
Repatha SureclickEvolocumab14$11,379
JardianceEmpagliflozin13$9,092
SotalolSotalol Hcl247$7,156
Flecainide Acetate86$4,535
Metoprolol Succinate289$4,155
Rosuvastatin Calcium116$1,685
Losartan Potassium150$1,570
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$1,378
Metoprolol Tartrate120$1,138
Digoxin50$1,063
Carvedilol101$885
Atorvastatin Calcium66$876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$535,122486 claims
Johnson & JohnsonXarelto$221$118,65190 claims
Boehringer IngelheimJardiance$125$9,09213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Tavares

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →